PATIENTS' PERSPECTIVES ON ORAL DECITABINE AND CEDAZURIDINE FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES

被引：1
|
作者：
Zeidan, A. [1 ]
Perepezko, K. [2 ]
Salimi, T. [3 ]
Washington, T. [3 ]
Epstein, R. [4 ]
机构：
[1] Yale Canc Ctr, Hematol, New Haven, CT USA
[2] CorEvitas Llc, Waltham, MA USA
[3] Taiho Oncol Inc, Princeton, NJ USA
[4] Epstein Hlth Llc, Woodcliff Lake, NJ USA
来源：
LEUKEMIA RESEARCH | 2023年 / 128卷
关键词：
D O I：
10.1016/j.leukres.2023.107127
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O14
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Patients' perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms
    Zeidan, Amer M.
    Perepezko, Kate
    Salimi, Tehseen
    Washington, Terri
    Epstein, Robert S.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2024, 15
  • [2] FDA Approval Summary: Decitabine and Cedazuridine Tablets for Myelodysplastic Syndromes
    Kim, Nina
    Norsworthy, Kelly J.
    Subramaniam, Sriram
    Chen, Haiyan
    Manning, Michael L.
    Kitabi, Eliford
    Earp, Justin
    Ehrlich, Lori A.
    Okusanya, Olanrewaju O.
    Vallejo, Jonathon
    Gehrke, Brenda J.
    de Claro, R. Angelo
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2022, 28 (16) : 3411 - 3416
  • [3] Real-World Treatment Patterns Among Patients with Myelodysplastic Syndromes Initiating Oral Decitabine and Cedazuridine or Intravenous/Subcutaneous Hypomethylating Agents
    Zeidan, Amer M.
    Costantino, Halley
    Modi, Kushal
    Salimi, Tehseen
    Washington, Terri
    Epstein, Robert S.
    BLOOD, 2023, 142
  • [4] Decitabine plus cedazuridine and venetoclax: the promise of an all-oral therapy for patients with myelodysplastic syndromes and chronic myelomonocytic leukaemia
    Assouline, Sarit
    LANCET HAEMATOLOGY, 2024, 11 (03): : e170 - e171
  • [5] Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
    Savona, Michael R.
    McCloskey, James K.
    Griffiths, Elizabeth A.
    Yee, Karen W. L.
    Al-Kali, Aref
    Zeidan, Amer M.
    Deeg, H. Joachim
    Patel, Prapti A.
    Sabloff, Mitchell
    Keating, Mary-Margaret
    Kim-Hien Dao
    Zhu, Nancy
    Gabrail, Nashat
    Fazal, Salman
    Maly, Joseph
    Odenike, Olatoyosi
    Kantarjian, Hagop M.
    DeZern, Amy E.
    O'Connell, Casey L.
    Roboz, Gail J.
    Busque, Lambert
    Wells, Richard A.
    Amin, Harshad
    Randhawa, Jasleen K.
    Leber, Brian
    Hao, Yong
    Keer, Harold N.
    Azab, Mohammad
    Garcia-Manero, Guillermo
    BLOOD, 2020, 136
  • [6] Decitabine in the treatment of myelodysplastic syndromes
    Santos, Fabio P. S.
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    Issa, Jean-Pierre
    Ravandi, Farhad
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (01) : 9 - 22
  • [7] Treatment Patterns and Characteristics Among Patients with Myelodysplastic Syndromes Initiating Oral Decitabine and Cedazuridine or Intravenous/Subcutaneous Hypomethylating Agents in a Real-World Setting
    Zeidan, Amer M.
    Divino, Victoria
    DeKoven, Mitch
    Wang, Elizabeth
    Chen, Justin
    Salimi, Tehseen
    Epstein, Robert S.
    BLOOD, 2022, 140 : 4047 - 4049
  • [8] Which myelodysplastic syndromes patients are candidates for treatment with decitabine?
    Luebbert, M.
    LEUKEMIA RESEARCH, 2007, 31 : S20 - S20
  • [9] The role of decitabine in the treatment of myelodysplastic syndromes
    Atallah, Ehab
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (01) : 65 - 73
  • [10] Decitabine treatment of patients with higher-risk myelodysplastic syndromes
    Steensma, David P.
    LEUKEMIA RESEARCH, 2009, 33 : S12 - S17
12345